Trial Profile
An Open-Label, Multicenter, Randomized, Controlled Study in Spontaneously Breathing Preterm Neonates With Respiratory Distress Syndrome to Compare Two Procedures for Porcine Surfactant (Poractant Alfa, CUROSURF®) Administration: A Less Invasive Method (LISA) During Non-invasive Ventilation (NIV) and the Conventional Administration During Brief Invasive Ventilation
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Poractant alfa (Primary)
- Indications Neonatal respiratory distress syndrome
- Focus Adverse reactions
- Acronyms LISPAP
- Sponsors Chiesi Farmaceutici
- 20 Sep 2022 Status changed from recruiting to discontinued.
- 03 Jun 2021 Status changed from not yet recruiting to recruiting.
- 30 Mar 2021 Planned End Date changed from 30 May 2025 to 30 Sep 2025.